Phospholipid PL1 是一种磷脂衍生的纳米颗粒，能够向 T 细胞传递共刺激受体 mRNA (CD137 或 OX40)。Phospholipid PL1 可诱导多种免疫细胞的激活，包括T细胞和树突状细胞 (DC)，以增强抗肿瘤免疫反应。
| 生物活性 | Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity[1]. |
体内研究
(In Vivo) | Phospholipid PL1 (10 μg mRNA/mouse; i.t.; 6 times every other day; for 60 d) improves the immunotherapy with an anti-CD137 Ab and antitumor activity with an anti-OX40 Ab in tumor models with better results obtained in the B16F10 melanoma model than the A20 lymphoma model[1].
| Animal Model: | B16F10 melanoma mouse model and A20 lymphoma mouse model (C57BL/6 mice)[1] | | Dosage: | Administration of PL1-CD137 + anti-CD137 Ab; PL1-CD137 (10 μg mRNA/mouse), and anti-CD137 Ab (16 μg/mouse) | | Administration: | Intratumoral injection; 6 times every other day; 60 days | | Result: | Dramatically decreased the tumor growth rate by 5-fold (18 days after inoculation), and increased the overall survival time in B16F10 melanoma model.
Resulted in a 2-fold decrease in the tumor growth rate (18d after inoculation) in A20 lymphoma model, without significant extension in the overall survival time. |
| Animal Model: | B16F10 melanoma mouse model and CT26 colon carcinoma mouse model (C57BL/6 mice)[1] | | Dosage: | Administration of PL1-OX40 + anti-OX40 Ab; PL1-OX40 (10 μg mRNA/mouse), and anti-OX40 Ab (8 μg/mouse) | | Administration: | Intratumoral injection; 6 times every other day; 60 days | | Result: | Significantly decreased the tumor growth and prolonged survival in comparison to treatment with PBS and PL1-OX40 + anti-OX40 Ab in both tumor models. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com